Loading market dashboard
Santhera Pharmaceuticals Holding AG
SPHDFHealthcareOTCCH
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Santhera Pharmaceuticals Holding AG (SPHDF) Q4 2025 Earnings Call Transcript
With eBay Inc (NASDAQ:EBAY, XETRA:EBA) set to report its first-quarter 2026 results on April 29, UBS has bumped its price target on the stock to $110 from...
The Swiss rare disease specialist expects to reach breakeven in the third quarter of 2026 without raising additional funds. Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0), the Swiss specialty pharma group listed on the SIX Swiss Exchange, has reconfirmed it expects to reach cash flow breakeven during the third quarter of 2026, requiring no additional fundraising, as its Duchenne muscular dystrophy (DMD) drug AGAMREE delivered revenues well ahead of guidance.
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on April 28, 2026, at 14:00 CEST / 13:00 BST / 08:00 EDT.
Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0), the Swiss rare disease specialist, has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommending that its Duchenne muscular dystrophy (DMD) treatment AGAMREE be approved for children from two years of age. DMD is a severe inherited muscle-wasting disease that progressively weakens skeletal, heart, and respiratory muscles, typically affecting boys from early childhood.
